Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion

Six-Month Primary End Point Results of a Phase III Study


      To assess efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema following branch retinal vein occlusion (BRVO).


      Prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trial.


      A total of 397 patients with macular edema following BRVO.


      Eligible patients were randomized 1:1:1 to receive monthly intraocular injections of 0.3 mg or 0.5 mg of ranibizumab or sham injections.

      Main Outcome Measures

      The primary efficacy outcome measure was mean change from baseline best-corrected visual acuity (BCVA) letter score at month 6. Secondary outcomes included other parameters of visual function and central foveal thickness (CFT).


      Mean (95% confidence interval [CI]) change from baseline BCVA letter score at month 6 was 16.6 (14.7–18.5) and 18.3 (16.0–20.6) in the 0.3 mg and 0.5 mg ranibizumab groups and 7.3 (5.1–9.5) in the sham group (P<0.0001 for each ranibizumab group vs sham). The percentage of patients who gained ≥15 letters in BCVA at month 6 was 55.2% (0.3 mg) and 61.1% (0.5 mg) in the ranibizumab groups and 28.8% in the sham group (P<0.0001 for each ranibizumab group vs sham). At month 6, significantly more ranibizumab-treated patients (0.3 mg, 67.9%; 0.5 mg, 64.9%) had BCVA of ≥20/40 compared with sham patients (41.7%; P<0.0001 for each ranibizumab group vs sham); and CFT had decreased by a mean of 337 μm (0.3 mg) and 345 μm (0.5 mg) in the ranibizumab groups and 158 μm in the sham group (P<0.0001 for each ranibizumab group vs sham). The median percent reduction in excess foveal thickness at month 6 was 97.0% and 97.6% in 0.3 mg and 0.5 mg groups and 27.9% in the sham group. More patients in the sham group (54.5%) received rescue grid laser compared with the 0.3 mg (18.7%) and 0.5 mg (19.8%) ranibizumab groups. The safety profile was consistent with previous phase III ranibizumab trials, and no new safety events were identified in patients with BRVO.


      Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid, effective treatment for macular edema following BRVO with low rates of ocular and nonocular safety events.

      Financial Disclosure(s)

      Proprietary or commercial disclosure may be found after the references.
      To read this article in full you will need to make a payment


      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Klein R.
        Retinopathy in a population-based study.
        Trans Am Ophthalmol Soc. 1992; 90: 561-594
        • Gewaily D.
        • Greenberg P.B.
        Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.
        Cochrane Database Syst Rev. 2009; 1 (CD007324)
        • Klein R.
        • Moss S.E.
        • Meuer S.M.
        • Klein B.E.
        The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study.
        Arch Ophthalmol. 2008; 126: 513-518
        • U.S. Census Bureau
        Annual Estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2007.
        (NC-EST2007-01. Release Date: May 1, 2008) (Accessed February 16, 2010)
        • Frangieh G.T.
        • Green W.R.
        • Barraquer-Somers E.
        • Finkelstein D.
        Histopathologic study of nine branch retinal vein occlusions.
        Arch Ophthalmol. 1982; 100: 1132-1140
        • Branch Vein Occlusion Study Group
        Argon laser photocoagulation for macular edema in branch vein occlusion.
        Am J Ophthalmol. 1984; 98: 271-282
        • Aiello L.P.
        • Avery R.L.
        • Arrigg P.G.
        • et al.
        Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
        N Engl J Med. 1994; 331: 1480-1487
        • Campochiaro P.A.
        • Hafiz G.
        • Shah S.M.
        • et al.
        Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.
        Mol Ther. 2008; 16: 791-799
        • Noma H.
        • Funatsu H.
        • Yamasaki M.
        • et al.
        Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.
        Am J Ophthalmol. 2005; 140: 256-261
        • Ozaki H.
        • Hayashi H.
        • Vinores S.A.
        • et al.
        Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates.
        Exp Eye Res. 1997; 64: 505-517
        • Brown D.M.
        • Kaiser P.K.
        • Michels M.
        • et al.
        • ANCHOR Study Group
        Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
        N Engl J Med. 2006; 355: 1432-1444
        • Rosenfeld P.J.
        • Brown D.M.
        • Heier J.S.
        • et al.
        • MARINA Study Group
        Ranibizumab for neovascular age-related macular degeneration.
        N Engl J Med. 2006; 355: 1419-1431
        • Early Treatment Diabetic Retinopathy Study Research Group
        Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1.
        Arch Ophthalmol. 1985; 103: 1796-1806
        • Signorini D.F.
        • Leung O.
        • Simes R.J.
        • et al.
        Dynamic balanced randomization for clinical trials.
        Stat Med. 1993; 12: 2343-2350
        • Chan A.
        • Duker J.S.
        • Ko T.H.
        • et al.
        Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography.
        Arch Ophthalmol. 2006; 124: 193-198
        • Antiplatelet Trialists' Collaboration
        Collaborative overview of randomized trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
        BMJ. 1994; 308: 81-106
      1. Lucentis.
        ([package insert]) Genentech, San Francisco2007 (Accessed February 15, 2010)